

Epidemiology and Treatment of Peripheral Neuropathy in Systemic Sclerosis

Bader A. AlMehmadi¹ , Fergus Z. To², Melanie A. Anderson³ , and Sindhu R. Johnson⁴ 

ABSTRACT. *Objective.* The epidemiology and treatment of peripheral neuropathy in systemic sclerosis (SSc) is poorly understood. The objectives of this study were to evaluate the incidence, prevalence, risk factors, and treatments of peripheral neuropathy in SSc.

Methods. A systematic review of MEDLINE, Embase, and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) databases for literature reporting peripheral neuropathy in SSc was performed. Studies evaluating incidence, prevalence, risk factors, and treatments were synthesized. A metaanalysis using a random effects model was used to evaluate the prevalence of peripheral neuropathy.

Results. This systematic review identified 113 studies that reported 949 of 2143 subjects with at least 1 type of peripheral neuropathy. The mean age was 48.5 years. The mean time between SSc onset and detection of peripheral neuropathy was 8.85 years. The pooled prevalence of neuropathy was 27.37% (95% CI 22.35–32.70). Risk factors for peripheral neuropathy in SSc included advanced diffuse disease, anti-centromere antibodies, calcinosis cutis, ischemia of the vasa nervorum, iron deficiency anemia, metoclopramide, pembrolizumab, silicosis, and uremia. There were 73 subjects with successful treatments (n = 36 restoring sensation, n = 37 restoring motor or sensorimotor function). Treatments included decompression surgery, prednisone, cyclophosphamide, carbamazepine, transcutaneous electrical nerve stimulation, tricyclic antidepressants, and intravenous Ig.

Conclusion. All-cause peripheral neuropathy is not uncommon in SSc. Compression neuropathies can be treated with decompression surgery. Observational data reporting immunosuppressives and anticonvulsants to treat peripheral neuropathy in SSc are limited and conflicting. Randomized controlled trials are needed to evaluate the efficacy of these interventions.

Key Indexing Terms: epidemiology, peripheral neuropathy, scleroderma, systemic sclerosis

Peripheral neuropathy encompasses a wide spectrum of clinical disorders affecting sensory, motor, and autonomic peripheral nerve fibers. Most peripheral neuropathies affect all fiber types to some extent. However, a single fiber type may be predominantly

or exclusively affected in some disorders. Peripheral neuropathies are also defined by the pattern of nerve fiber involvement. Some disorders involve single individual peripheral nerves (mononeuropathies), and some involve numerous individual peripheral nerves (the mononeuritis multiplex syndrome). In addition, peripheral nerve disorders can involve the brachial plexus, lumbosacral plexus, or they can involve a single root, resulting in signs and symptoms in 1 limb. This diverse array of possible etiologies can make the diagnosis of peripheral neuropathies challenging. Nevertheless, the diagnosis can be facilitated with a systematic approach that classifies the peripheral neuropathy on the basis of clinical features, taking into account the type of peripheral nerve fiber that may be involved (i.e., sensory, motor, or autonomic), the distribution or pattern of peripheral nerve fiber involvement (generalized and symmetrical vs asymmetrical and multifocal), and the mode of evolution (acute, subacute, or chronic). Nerve conduction studies can be helpful in confirming the diagnosis, and in defining the nature and extent of the peripheral neuropathy. Peripheral nerve disorders are relatively common conditions that affect 2.4% of the population.¹ However, the prevalence increases to 8.0% with advancing age. Management of the peripheral neuropathy is directed first at the specific cause if it is treatable; and second at the alleviation of symptoms, including

SRJ is supported by a Canadian Institutes of Health Research New Investigator Award, Gurmej Kaur Dhandra Scleroderma Research Award, and the Oscar and Elanor Markovitz Scleroderma Research Fund.

¹B.A. AlMehmadi, MBBS, Toronto Scleroderma Program, Mount Sinai Hospital, Toronto Western Hospital, Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada, and College of Medicine, Majmaah University, Saudi Arabia; ²F.Z. To, MD, BSc, Toronto Scleroderma Program, Mount Sinai Hospital, Toronto Western Hospital, Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; ³M.A. Anderson, MLIS, Medical Library, University Health Network, University of Toronto, Toronto, Ontario, Canada; ⁴S.R. Johnson, MD, PhD, Toronto Scleroderma Program, Mount Sinai Hospital, Toronto Western Hospital, Division of Rheumatology, Department of Medicine, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.

The authors declare that they have no competing interests relevant to this article.

Address correspondence to Dr. S.R. Johnson, Division of Rheumatology, Ground Floor, East Wing, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON M5T 2S8, Canada. Email: Sindhu.Johnson@uhn.ca.

Accepted for publication June 9, 2021.

managing neuropathic pain, and bracing and physical therapy for weakness.

Systemic sclerosis (SSc) is an autoimmune disease characterized by vasculopathy, fibrosis, and immune abnormalities.² Affected organs include the skin, lungs, heart, digestive system, kidneys, muscles, joints, and nervous system. Neurologic involvement in SSc includes cranial, entrapment, peripheral, cutaneous, and autonomic neuropathies, whereas central nervous system (CNS) involvement includes headache, seizure, stroke, vascular disease, radiculopathy, and myelopathy. Estimates of the frequency of neurologic involvement in patients with SSc vary widely, but CNS involvement due to SSc is rare. A systematic review of the literature was conducted to synthesize data evaluating the epidemiology of peripheral neuropathy and treatment options used in SSc.

METHODS

Literature search. A literature search was conducted through the University Health Network library with the assistance of an information specialist. The search included Ovid MEDLINE from 1946 to September 2020, including the Epub Ahead of Print and In-Process and Other Non-Indexed Citations (inception to September 2020); Embase (1974 to September 2020); and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) with full text (inception to September 2020). The following keywords were used in the database search: scleroderma, systemic sclerosis, CREST (calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, telangiectasias), sclerodactyly, Raynaud, calcinosis, peripheral nervous system diseases, peripheral neuropathy, tarsal tunnel, carpal tunnel, cubital tunnel, neuropathy, mononeuropathy, polyneuropathy, radiculopathy, and myelopathy. The search was restricted to humans, but no language restriction was applied.

Study selection. Titles and abstracts were screened by 2 investigators independently to identify studies that described peripheral neuropathy in SSc. Inclusion criteria were (1) peer reviewed observational studies (cohort and case-control studies), randomized controlled trials (RCTs), case reports, or case series; and (2) report of peripheral neuropathy by symptoms and clinical examination, nerve conduction studies, or other detection tools. The 2 independent reviews were compared, and discrepancies were resolved by consensus or inclusion of a third investigator, as needed. Mixed connective tissue disease, central neuropathy, and myelopathies were excluded.

Data abstraction. Two investigators (BAA, FZT) independently reviewed each abstract and applied the inclusion and exclusion criteria to identify relevant studies for full review. A standardized data abstraction form was used to collect data on the study design, sample size, presence of control groups, incidence, prevalence, patterns of neuropathy, risk factors, and treatment.

Outcomes. A standardized form was used to abstract the prevalence, incidence, and risk factors of peripheral neuropathy in SSc, as well as treatments and outcomes.

Statistical analysis. Metaanalyses were evaluated for heterogeneity using the *Q* and *I*² tests.³ Influential analysis was initially conducted to see the effect of each study; the Baujat plot identified identified 2 studies that were contributing to high heterogeneity. We used the suggested criteria of 25% (low), 50% (moderate), and 75% (high) for different levels of heterogeneity. A random effects metaanalysis was performed using the Paule-Mandel estimator on the final studies,⁴ whereas the CIs of τ and τ^2 were adjusted using the Biggerstaff and Jackson method. Prediction intervals are also reported for the random effects model.⁵ Publication bias was assessed visually by inspecting a funnel plot and additionally by Egger test,⁶ as well as Trim and Fill and Fail Safe N methods.⁷ Multiple metaregression was also used to

assess the significance of different moderators. A *P* value < 0.05 was considered statistically significant. The data were analyzed using R Core Team (R Foundation for Statistical Computing).

RESULTS

Of the 6342 studies identified through a systematic review of the literature, 113⁸⁻¹²⁰ were identified for full review (Figure 1). A total of 2143 subjects were included in the studies reviewed, of which 949 subjects were diagnosed with at least 1 type of peripheral neuropathy (Supplementary Table 1, available with the online version of this article). The mean age was 48.5 years. Fifty-one studies reported peripheral neuropathy in 1030 subjects with limited SSc^{8-15,17-29,31-33,35-40,42-60,68,74,80,83,85,88,93-95,98,99,107} and 53 studies reported peripheral neuropathy in 607 subjects with diffuse SSc (dSSc).^{9,10,12,18,20,22,24,25,30,31,33,35,36,38,41,44,45,48,49,51,53-55,57,59,61-69,71,74,76-78,81,82,90,91,94,95,107,108,114-118,120} At least 5 juvenile SSc subjects with peripheral neuropathy were found in 4 studies,^{78,79,116,120} 4 studies reported peripheral neuropathy in 22 subjects with morphea,^{48,79,108,113} and 3 studies reported peripheral neuropathy in 81 subjects with SSc sine scleroderma.^{36,54,70} Study design included 49 case reports,^{8,14,15,17,23,27-31,37,39,40,42,43,47,52,56,58,60,61,63-67,69,70-73,76,78-91,115,117,118} 23 case series,^{11,16,20,22,26,31,32,34,41,46,50,62,68,77,92-95,97-99,114,120} 39 observational studies,^{9,10,12,13,18,19,21,24,25,33,35,36,38,44,45,48,49,51,53-55,57,59,74,96,100-106,108-113,116} and 51 studies for therapeutics.^{8,11,14,15,17,21,23,29,31,32,34,37,39-43,46-48,60-62,64,66,68,69,71-74,76,81,84-86,88,90-95,99,101,102,107,114-116,118} No RCTs were identified.

The average duration between SSc onset and the detection of peripheral neuropathy was 8.85 years. Twenty-four studies reported a neuropathy onset ranging from 3 months to 5 years before SSc was diagnosed,^{8,11,22,29,31,46,48,50,56,58,63,64,66,69,71,77,78,80,82,83,87,89,94,114} 4 studies reported diagnosing SSc and neuropathy at the same time,^{34,62,93,98} and the remaining studies reported neuropathy 1 month to 59 years after the diagnosis of SSc. The most frequent modalities used to detect and assess neuropathy were history and physical examination in symptomatic subjects (*n* = 339),^{8,11,13-17,20-32,34,37,40-48,50,52,53,56-64,66-74,76-91,93-95,97-99,101,103-105,109-111,114-116,118,120} nerve conduction studies (NCS; *n* = 173),^{8,11,13-17,20-34,37,40-50,52,53,56-64,66-74,76-84,86,88,93,94,98,100,105,108,114,115,120} and nerve and skin biopsies (*n* = 117).^{19,21,31,35,41,42,49,52,56,64,79,82,88,89,93,94,112,113,116,117} Imaging techniques included radiographs (6.3%),^{17,47,60,65,81,85,91} computed tomography scans (5.4%),^{17,23,72,81,90,91} ultrasound (4.5%),^{10,13,57,92,105} and magnetic resonance imaging (4.5%).^{42,57,69,91,120} Imaging modalities were mostly used where compression neuropathy was suspected.

Peripheral neuropathies were categorized as compression vs noncompression neuropathies. Compression neuropathies were reported in 26.5% of the studies.^{10,11,13,17,23,30,31,34,40,43,46,47,50,56,57,60,64,72,74,77,81,84,85,90,91,95,101,105,118,120} Median nerve entrapment (carpal tunnel syndrome [CTS]) was the most common form of compression neuropathy (*n* = 216; Table 1).^{10,11,13,31,34,46,50,56,57,64,74,77,84,95,101,105,118,120} Causes of entrapment included calcinosis cutis (most common)^{17,47,57,60,72,85,91} and soft tissue thickening.^{10,13,40,74,84} Trigeminal neuralgia may also occur as a result of nerve entrapment secondary to calcinosis or tissue fibrosis.^{8,14,17,19,30,31,34,35,37,43,46,47,52,57-60,63,70,72-74,80-82,84,85,90,91,93,94,99,104,111,113,116,118,120}




Figure 1. PRISMA flow diagram of systematic review results. CINAHL: Cumulative Index to Nursing and Allied Health Literature; PRISMA: Preferred Reporting Items for Systematic reviews and Meta-Analyses; SSc: systemic sclerosis.

Table 1. Compression and noncompression neuropathies in systemic sclerosis.

Compression Neuropathy	Noncompression Neuropathy
Trigeminal neuropathy	Trigeminal neuropathy
Carpal tunnel syndrome	Sensorimotor neuropathy
Ulnar nerve entrapment	Brachial plexopathy
Tarsal tunnel syndrome	Sensory ataxic neuropathy
Ilioinguinal nerve entrapment	Multiple mononeuropathies
Popliteal nerve palsy	Sensory motor plexopathy
Cutaneous neuropathy	Optic neuropathy
	Digital neuropathy
	Sensory neuropathy
	Polyneuropathy
	Cutaneous neuropathy
	Axonal polyneuropathy
	Fourth cranial nerve palsy
	Meralgia paraesthetica
	Damaged cutaneous peripheral nerves
	Digital neurovascular dysfunction
	Neuropathic fecal incontinence
	Painful feet paresthesia

The most common type of noncompression neuropathy was trigeminal neuropathy (n = 100).^{9,22,23,25,26,29,31,58,61-63,66-69,73,78,79,83,87,95,97,99,120} Several etiologies were proposed including nerve fibrosis secondary to tissue edema and

vasculitis,^{8,13,15,19,21,27,32,34,35,39,40,48,56,57,63,73,80,88,99,113,117} as well as nerve ischemia due to microangiopathy.^{9,10,14,15,23,24,31,33,37,44,49,52,53,57,59,73,88,94,105} Mononeuropathy was found in the majority of subjects (n = 369),^{9,11,13,16-19,22-24,26,27,29-34,37,39,40,46,47,50,57-60,62-70,73,74,77,78,83-85,87,95,97-99,101,103,105,118,120} multiple mononeuropathies in 143 subjects,^{14-16,21,31,34,35,41,53,61,79,82,92,95,98,100,102} and polyneuropathy in 202 subjects.^{16,25,26,28,31,38,40,42-44,48,49,51,52,55,56,68,71,72,76,80,81,86,88-91,94,96,104,105,109-111,114,115,117,120} When neuropathies were assessed based on small and large fibers, the most common type found was small fiber neuropathy (n = 556),^{9-16,18,19,21-24,26,27,29-31,34,35,38,41,43,44,46-51,53,55,57,58,62-64,66-70,73,74,77-79,83,87,92,95,97-104,106,109,111,113,118,120} whereas large fiber neuropathy was found in 231 subjects (data not shown).^{8,16,17,21,25,26,28,31-33,37,39-42,48,49,52,56,59-61,65,68,71,72,74,76,79-82,84-86,88-92,94,96,98,100,102,105,110,115,120}

Risk factors. The most frequent risk factor for compression neuropathy in SSc was calcinosis cutis.^{17,72,88} Risk factors for noncompression neuropathies include advanced diffuse disease, anticentromere antibodies, ischemia of the vasa nervorum, iron deficiency anemia, reduced nerve density, metoclopramide, pembrolizumab, silicosis, and uremia (Table 2).

Treatment. There were 68 patients with reported success of treatments in the literature, including 41 patients who had success in restoring sensation.^{8,11,14,15,17,23,34,40,42,43,48,56,60,64,73,74,84,88,90,91,101} These patients had CTS, brachial plexopathy, optic neuropathy, ulnar nerve compression, trigeminal neuropathy, axonal

Table 2. Risk factors for noncompression peripheral neuropathy in SSc.

Study	Neuropathy Risk Factor	Method of Assessment
Manneschi 2005 ³⁵	Advanced dSSc	N/A
Del Rosso 2003 ¹⁸	Anticentromere antibody	Indirect immunofluorescence
Bandinelli 2010 ¹⁰	Ischemia of vasa nervorum	Ultrasound
Ostojic 2013 ⁴⁴	Metoclopramide and iron deficiency anemia	N/A
Barbosa 2017 ¹¹⁴	Pembrolizumab	N/A
Bignotti 2015 ¹³	Reduced nerve density	Ultrasound
Agarwal 1987 ⁶¹	Silicosis	N/A
Averbuch-Heller 1992 ¹²⁰	Uremia	Blood level

dSSc: diffuse systemic sclerosis; N/A: not applicable; SSc: systemic sclerosis.

sensory neuropathy, lumbosacral plexopathy, cervical radiculopathy, and cauda equina. Thirty-three patients had improvement in motor or sensorimotor neuropathies.^{31,37,40,64,75,88,91,94,107,115} These patients had neuromyotonia, CTS, 4th nerve palsy, lumbosacral plexopathy, cauda equina, and gastric myoelectric activity abnormalities (Table 3). Out of the 68 patients, 17 had documented successful surgeries (14 for sensory neuropathies^{11,17,34,40,43,60,64,74,84,90,91} and 3 for sensorimotor^{40,64,91}), and all the surgeries were performed on neuropathies caused by nerve compression.^{17,31,34,40,43,47,60,72,74,84,90,91,118}

Immunosuppression was the treatment of choice for noncompression neuropathies caused by tissue edema, vasculitis, and microangiopathy.^{8,15,21,32,34,39,40,73,88,94} The most commonly used medication in cases of neuropathy with successful outcomes was prednisone (n = 11), where it was used in 7 patients with sensory neuropathies (5 as monotherapy,^{34,48,73,88} 1 in combination with cyclophosphamide [CYC],⁸ and 1 in combination with azathioprine¹⁵), and in 4 patients with motor neuropathies (3 as

monotherapy^{31,88,94} and 1 in combination with CYC⁷⁵). Only complete resolution of symptoms was considered a successful outcome. CYC use was reported in 4 case reports.^{8,65,75,119} Nonimmunosuppressive therapy for noncompression neuropathies included amitriptyline, pregabalin, gabapentin, tricyclic antidepressants, and transcutaneous electrical nerve stimulation. Treatments for compression and noncompression peripheral neuropathies are summarized in Tables 3 and 4.

Metaanalysis. The pooled prevalence of neuropathy using the random effects model was 27.37% (95% CI 22.35–32.70) with the 95% prediction interval of 17.54–38.47%. The *I*² was 19% (95% CI 0.00–58.50) with *P* = 0.27. Results are presented in a forest plot (Figure 2). Egger test (*P* = 0.65) and funnel plot showed that publication bias was not an issue in this research. The results of the Fail Safe N method (N = 1720, *P* = 0.05) further suggest that the conclusion of our metaanalysis may not be susceptible to publication bias. We tested different moderators (sex, publication year, age, duration of disease, and study

Table 3. Treatment of compression peripheral neuropathy in systemic sclerosis and outcomes.

Study	Treatment Drug	Sensory Outcome	Motor Outcome	MRC at Baseline	MRC Posttreatment	Assessment Tool/Parameter
Barr 1988 ¹¹	Decompression surgery	Partial improvement	N/A	N/A	N/A	Symptoms
Barr 1988 ¹¹	Decompression surgery	Success	N/A	N/A	N/A	Symptoms
Berth-Jones 1990 ⁶⁴	Decompression surgery	Success	Success	N/A	N/A	Symptoms
Chammas 1995 ¹⁷	Decompression surgery	Success	N/A	N/A	N/A	Symptoms
Ko 1996 ⁸⁴	Decompression surgery	Success	N/A	N/A	N/A	Symptoms
Lima 2005 ⁷²	Posterior cervical-thoracic laminectomy	Failure	Failure	N/A	N/A	Symptoms
Machet 1992 ³⁴	Decompression surgery	Success	N/A	N/A	N/A	Symptoms
Machet 1992 ³⁴	Decompression surgery	Success	N/A	N/A	N/A	Symptoms
Machet 1992 ³⁴	Decompression surgery	Success	N/A	N/A	N/A	Symptoms
Mondeli 1995 ⁷⁴	Decompression surgery	Failure	N/A	N/A	N/A	Symptoms
Mondeli 1995 ⁷⁴	Decompression surgery	Success	N/A	N/A	N/A	Symptoms
Mondeli 1995 ⁷⁴	Decompression surgery	Success	N/A	N/A	N/A	Symptoms
Mouthon 2000 ⁴⁰	Ulnar arcade resection	Success	Success	N/A	N/A	Symptoms
Ortiz 1991 ⁴³	Surgery (aneurysm)	Success	N/A	N/A	N/A	Symptoms
Pinstein 1989 ⁹⁰	Surgery	Success	N/A	N/A	N/A	Symptoms
Polio 1989 ⁴⁷	Surgery	Partial improvement	N/A	N/A	N/A	Symptoms
Shibuya 2006 ⁹¹	Surgery	Success	Success	3 to 4	5	Symptoms
Thurman 1991 ⁶⁰	Surgery	Success	Partial improvement	N/A	N/A	Symptoms

N/A: not applicable; MRC: Medical Research Council.

Table 4. Treatment of noncompression peripheral neuropathy in systemic sclerosis and outcomes.

Study	Treatment Drug	Sensory Outcome	Motor Outcome	MRC at Baseline	MRC Posttreatment	Assessment Tool/Parameter
Immunosuppressives						
Agarwal 1987 ⁶¹	D-penicillamine	Partial improvement	Partial improvement	N/A	N/A	Symptoms
Allanore 2002 ⁸	Prednisone and cyclophosphamide	Success	Partial improvement	3 of 5	4 of 5	Symptoms
Andreou 2012 ¹¹⁹	Cyclophosphamide	N/A	Partial improvement	N/A	N/A	Gait
Andreadou 1971 ⁶²	Prednisone	N/A	No change	N/A	N/A	Blink reflex
Ashworth 1971 ⁶²	Prednisone	N/A	No change	N/A	N/A	Blink reflex
Barbosa 2017 ¹¹⁴	IVIg and mycophenolic acid	N/A	Failure	N/A	N/A	Power
Barbosa 2017 ¹¹⁴	Prednisone	N/A	Failure	N/A	N/A	Power
Birk 1995 ⁶⁵	Prednisolone and cyclophosphamide	N/A	Failure	N/A	N/A	Symptoms
Boschi 1993 ¹⁵	Prednisone and azathioprine	Success	N/A	N/A	N/A	Visual acuity
Boschi 1993 ¹⁵	Prednisone and azathioprine	Failure	N/A	N/A	N/A	Visual field
Burke 1979 ⁶⁶	D-penicillamine	Failure	N/A	N/A	N/A	Examination
Knupp-Oliviera 1999 ⁷¹	Prednisone	Failure	Partial improvement	N/A	N/A	Writing and walking
Lecky 1987 ⁹⁵	Prednisone	Failure	N/A	N/A	N/A	Symptoms
Lee 1984 ³¹	Prednisone	Not documented	Success	Not documented	4+	Walking
Levy 2005 ⁸⁶	IVIg	Partial improvement	Partial improvement	N/A	N/A	EMG and symptoms
Levy 2005 ⁸⁶	Prednisone	Failure	Failure	N/A	N/A	Symptoms
Machet 1992 ³⁴	Local corticotherapy	Partial improvement	N/A	N/A	N/A	Symptoms
Machet 1992 ³⁴	Local corticotherapy	Success	N/A	N/A	N/A	Symptoms
Miguel 2017 ³	Prednisone	Success	N/A	N/A	N/A	Symptoms
Mondeli 1995 ⁷⁴	Local injections of 40 mg triamcinolone acetonide	Failure	N/A	N/A	N/A	Symptoms
Moore 1989 ⁸⁸	Prednisone 40 mg	Success	Success	3 of 5	5 of 5	Symptoms
Moulick 2013 ³⁹	Prednisone 1 mg/kg	Partial improvement	N/A	N/A	N/A	Vision
Mouthon 2000 ⁷⁵	Cyclophosphamide and prednisone	Failure	Success	N/A	N/A	Symptoms
Nitra 1996 ⁴¹	Prednisone 40 mg and prostaglandin E	Failure	N/A	N/A	N/A	Symptoms
Nitra 1996 ⁴¹	Prednisone 40 mg and prostaglandin E	Partial improvement	N/A	N/A	N/A	Symptoms
Nobuhara 2006 ⁶²	IVIg	Success	N/A	N/A	N/A	Symptoms
Sukemik 1987 ³⁶	Penicillamine	Failure	N/A	N/A	N/A	Impotence
Sukemik 1987 ³⁶	Penicillamine	Success	N/A	N/A	N/A	Carpal tunnel symptoms
Poncellet 2003 ⁴⁸	Prednisone	Success	N/A	N/A	N/A	Symptoms
Poncellet 2003 ⁴⁸	Prednisone	Success	N/A	N/A	N/A	Symptoms
Rudusky 1964 ⁷⁶	Prednisone	Failure	Failure	0	0	Symptoms
Di Trapani 1986 ⁹⁴	Prednisone	N/A	Success	2 to 3	5	Symptoms
Nonimmunosuppressives						
Benito-León 1999 ¹¹⁵	Carbamazepine	N/A	Success	N/A	N/A	Symptoms
Benito-León 1999 ¹¹⁵	Hydroquinine and tetrazeepam	N/A	Failure	N/A	N/A	Symptoms
Bondavalli 1997 ¹⁴	Amitriptyline	Failure	N/A	N/A	N/A	Sensation
Bondavalli 1997 ¹⁴	Amitriptyline	Success	N/A	N/A	N/A	Pain
Butt 2015 ⁹²	Sacral nerve stimulation	N/A	10 failures	N/A	N/A	Fecal incontinence
DeLea 2011 ¹⁰¹	Hydrodissection with lidocaine followed by injection of triamcinolone	12 successes	N/A	N/A	N/A	Pain score
Fischhoff 2000 ²³	Gabapentin	Success	N/A	N/A	N/A	Pain
Jimenez-Moreno 1998 ⁶⁹	Carbamazepine	Failure	N/A	N/A	N/A	Symptoms

Table 4. Continued.

Study	Treatment Drug	Sensory Outcome	Motor Outcome	MRC at Baseline	MRC Posttreatment	Assessment Tool/Parameter
Kabadi 1977 ²⁹	Carbamazepine	Partial improvement	N/A	N/A	N/A	Symptoms
Kabadi 1977 ²⁹	Levodopa	Failure	N/A	N/A	N/A	Symptoms
Kabadi 1977 ²⁹	Phenytoin	Failure	N/A	N/A	N/A	Symptoms
Lecky 1987 ⁹⁵	Carbamazepine	Failure	N/A	N/A	N/A	Symptoms
Lecky 1987 ⁹⁵	Carbamazepine	Failure	N/A	N/A	N/A	Symptoms
Lecky 1987 ⁹⁵	Carbamazepine	Failure	N/A	N/A	N/A	Symptoms
McNearney 2013 ¹⁰⁷	Transcutaneous electrical nerve stimulation (TENS)	N/A	17 successes	N/A	N/A	Improved GMA scores, lowered plasma VIP, motilin and IL-6 levels and improved association between GMA and sympathovagal balance
Mejias 1986 ³⁷	Lens prism	N/A	Success	N/A	N/A	Improved vertical diplopia
Miguel 2017 ⁷³	Pregabalin, duloxetine, repeated infusions of procaine and lidocaine, and local therapy with capsaicin, red light therapy, connective tissue massages or transcutaneous electrical nerve stimulation of the face	Failure	N/A	N/A	N/A	Symptoms
Mouthon 2000 ⁴⁰	Ulnar arcade resection	Success	Success	N/A	N/A	Symptoms
Poncelet 2003 ⁴⁸	Gabapentin or tricyclic antidepressants	Failure	N/A	N/A	N/A	Symptoms
Poncelet 2003 ⁴⁸	Gabapentin or tricyclic antidepressants	Failure	N/A	N/A	N/A	Symptoms
Poncelet 2003 ⁴⁸	Gabapentin or tricyclic antidepressants	Success	N/A	N/A	N/A	Symptoms
Poncelet 2003 ⁴⁸	Gabapentin or tricyclic antidepressants	Success	N/A	N/A	N/A	Symptoms
Poncelet 2003 ⁴⁸	Gabapentin or tricyclic antidepressants	Success	N/A	N/A	N/A	Symptoms
Poncelet 2003 ⁴⁸	Gabapentin or tricyclic antidepressants	Success	N/A	N/A	N/A	Symptoms
Poncelet 2003 ⁴⁸	Gabapentin or tricyclic antidepressants	Success	N/A	N/A	N/A	Symptoms
Poncelet 2003 ⁴⁸	Gabapentin or tricyclic antidepressants	Success	N/A	N/A	N/A	Symptoms
Poncelet 2003 ⁴⁸	Lidocaine patch	Success	N/A	N/A	N/A	Symptoms
Vicente 1991 ⁹⁹	Carbamazepine and amitriptyline	Failure	N/A	N/A	N/A	Symptoms

EMG: electromyography; IL: interleukin; IVIG: intravenous immunoglobulin; GMA: gastric myoelectrical activity; MRC: Medical Research Council; N/A: not applicable; VIP: vasoactive intestinal peptide.




Figure 2. Forest plot of random effects model showing the pooled prevalence and prediction interval.

design) to explain the 19% heterogeneity. Results of metaregression showed that collectively the amount of heterogeneity explained by all these moderators was $R^2 = 98.77\%$, but overall the tests for moderators was not significant ($P = 0.67$). When multimodel inference was applied to observe which predictors were important, results showed that age was the most important predictor of neuropathy, followed by male sex, then female sex, and last, duration of disease.

DISCUSSION

Our study synthesizes the literature on the epidemiology and treatment of peripheral neuropathy in SSc. First, we found that peripheral neuropathy is not uncommon in SSc, with a pooled prevalence of 27.37%. Compared to a general population prevalence of 2–8%, peripheral neuropathy appears to occur more frequently in SSc. Peripheral neuropathy in SSc has several different etiologies including nerve compression by soft tissue swelling, tissue fibrosis or calcinosis cutis, traumatic injury, medication adverse effects, metabolic sequelae, and ischemia. Peripheral neuropathy was detected mostly in the first decade of the disease course (mean 8.85 yrs from the onset of SSc). Modalities most frequently used to detect peripheral neuropathy in SSc were physical examination, NCS, electromyography, and biopsy.

Peripheral neuropathy in the context of SSc can be categorized as compression or noncompression neuropathies. Calcinosis was the most-reported cause of compression neuropathy, but other causes of compression included soft tissue thickening, edema, and fibrosis. The most common entrapment neuropathy in SSc was CTS, which may present prior to the diagnosis of SSc. Compression neuropathies were mostly successful when treated by surgical decompression. Compression neuropathies, such as CTS, are well recognized in SSc and treatment well established.

In contrast, noncompression peripheral neuropathies in SSc may occur secondary to traumatic injury, adverse effects of medication, metabolic sequelae, or ischemia, and therefore have different risk factors. The noncompression peripheral polyneuropathies, consisting of sensory, mixed sensory and motor, and mononeuritis multiplex, were more common in dSSc. A symmetric, sensory polyneuropathy was the noncompression

neuropathy most frequently associated with SSc. A number of risk factors and etiologies have been implicated in the development of noncompression peripheral neuropathy in SSc. Complications of organ damage in SSc have also resulted in peripheral neuropathy, including renal involvement with hypertensive and/or uremic neuropathy; gastrointestinal tract involvement with malabsorption and subsequent myelopathy; and vitamin E, cyanocobalamin, or calciferol deficiency.^{74,120} Peripheral neuropathy may also be caused by microangiopathy leading to nerve ischemia,^{14,21,35,53,68,73,74,88,94,120} or as a result of therapies used in SSc, such as colchicine and penicillamine.^{74,120}

Mononeuropathy, or mononeuritis multiplex, may occur as a manifestation of vasculitis and was more frequent in patients with limited SSc. Since vasculitis is an uncommon manifestation of SSc, other overlapping diseases such as systemic lupus erythematosus, or a concomitant disease such as cryoglobulinemia due to hepatitis C infection, should be considered. Cranial neuropathies have also been reported in SSc. The most commonly involved cranial neuropathy was the trigeminal nerve, with dysfunction of the optic, oculomotor, trochlear, abducens, facial, glossopharyngeal, and auditory nerves. Symptoms of trigeminal neuropathy included slowly progressive unilateral or bilateral facial numbness, frequently with associated pain and paresthesia.

There are few reports of peripheral nerve pathology in patients with SSc. Findings include increased collagen and amorphous substance in the endoneurium, loss of myelinated fibers, intimal thickening, adventitial edema, diffuse hyalinosis of endoneurial and perineurial blood vessels, and necrotizing vasculitis (very rare).^{21,121,122} The treatment for compression peripheral neuropathy is most frequently decompression surgery. Medications used in the treatment of noncompressive peripheral neuropathies have included corticosteroids, CYC, amitriptyline, gabapentin, methotrexate, and anticonvulsants.

This comprehensive systematic review synthesizes what is known about the epidemiology and treatment of peripheral neuropathy on SSc. This may be of value to clinicians who face this clinical challenge. However, this study has a few limitations that should be considered. First, the literature reporting peripheral neuropathy in SSc is limited by the large number of case reports and the lack of RCTs. The literature describing the

frequency of peripheral neuropathy in SSc is largely descriptive and of poor methodological quality. As a result, our estimate of the frequency of all-cause peripheral neuropathy is imprecise. Attempts to make estimates of peripheral neuropathy by etiology would be even more imprecise. Second, the studies were variable in their use of physician diagnosis or classification criteria for SSc as inclusion criteria. Nearly all the studies predated the most recent 2013 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for SSc. The main messages we wish to express is that all-cause peripheral neuropathy occurs in SSc and is not uncommon. Peripheral neuropathy in SSc warrants better investigation of epidemiology and treatment. We have found evidence of potential therapeutic benefit of immunosuppressive and anticonvulsive medications, and demonstrated clinical equipoise regarding the preferred treatment regimen.¹²³

In conclusion, all-cause peripheral neuropathy appears to be more common in SSc than in the general population. Observational data suggest that compression neuropathies can be successfully treated with decompression surgery. The evidence supporting immunosuppressives and anticonvulsants to treat peripheral neuropathy in SSc is limited and conflicting. These data provide enough evidence of effect to justify RCTs to evaluate the efficacy of these interventions.

ONLINE SUPPLEMENT

Supplementary material accompanies the online version of this article.

REFERENCES

- Hughes RAC. Peripheral neuropathy. *BMJ* 2002;324:466-9.
- Proudman SM, Huq M, Stevens W, Wilson ME, Sahhar J, Baron M, et al; Australian Scleroderma Interest Group (ASIG), Canadian Scleroderma Research Group (CSRG), EULAR Scleroderma Trials and Research group (EUSTAR), Singapore Scleroderma Workgroup (SCORE). What have multicentre registries across the world taught us about the disease features of systemic sclerosis? *J Scleroderma Relat Disord* 2017;2:169-82.
- Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557-60.
- Veroniki AA, Jackson D, Viechtbauer W, Bender R, Bowden J, Knapp G, et al. Methods to estimate the between-study variance and its uncertainty in meta-analysis. *Res Synth Methods* 2016;7:55-79.
- Nagashima K, Noma H, Furukawa TA. Prediction intervals for random-effects meta-analysis: a confidence distribution approach. *Stat Methods Med Res* 2019;28:1689-702.
- Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. *Clin Exp Rheumatol* 2001;54:1046-55.
- Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics* 2000;56:455-63.
- Allanore Y, Zuber M, Kahan A. Brachial plexopathy associated with systemic sclerosis. *Clin Rheumatol* 2002;21:401-2.
- Bajocchi G, Terlizzi R, Zanigni S, Barletta G, Grimaldi D, Pierangeli G, et al. Evidence of a selective nociceptive impairment in systemic sclerosis. *Clin Exp Rheumatol* 2009;27 Suppl 54:9-14.
- Bandinelli F, Kaloudi O, Candelieri A, Conforti ML, Casale R, Cammarata S, et al. Early detection of median nerve syndrome at the carpal tunnel with high-resolution 18 MHz ultrasonography in systemic sclerosis patients. *Clin Exp Rheumatol* 2010;28 Suppl 62:S15-8.
- Barr WG, Blair SJ. Carpal tunnel syndrome as the initial manifestation of scleroderma. *J Hand Surg Am* 1988;13:366-8.
- Bienias P, Ciurzyński M, Głinska-Wielochowska M, Korczak D, Kalińska-Bienias A, Gliński W, et al. Heart rate turbulence impairment and ventricular arrhythmias in patients with systemic sclerosis. *Pacing Clin Electrophysiol* 2010;33:920-8.
- Bignotti B, Ghio M, Panico N, Tagliafico G, Martinoli C, Tagliafico A. High-resolution ultrasound of peripheral nerves in systemic sclerosis: a pilot study of computer-aided quantitative assessment of nerve density. *Skeletal Radiol* 2015;44:1761-7.
- Bondavalli P, Parodi A, Rebori A. Peripheral neuropathy in scleroderma successfully treated with amitriptyline. *Int J Dermatol* 1997;36:234-5.
- Boschi A, Snyers B, Lambert M. Bilateral optic neuropathy associated with the CREST variant of scleroderma. *Eur J Ophthalmol* 1993;3:219-22.
- Morer IC, Marco JV, Aznar JLH, Lafita CA, Caballo RB, Juste AO. [Neurological involvement in progressive systemic sclerosis]. [Article in Spanish] *Rev Clin Esp* 2003;203:373-7.
- Chammas M, Meyer zu Reckendorf G, Allieu Y. Compression of the ulnar nerve in Guyon's canal by pseudotumoral calcinosis in systemic scleroderma. *J Hand Surg Am* 1995;20:794-6.
- Del Rosso A, Bertinotti L, Pietrini U, Messori A, Fanciullacci M, Casale R, et al. Pupillo-cycnetic activity of substance P in systemic sclerosis. *J Rheumatol* 2003;30:1231-7.
- Del Rosso A, Ibba Manneschi L, Tani A, Nosi D, Franca Milia A, Generini S, et al. [Peripheral nervous system in limited systemic sclerosis]. [Article in Italian] *Reumatismo* 2004;56:247-52.
- Dierckx RA, Aichner F, Gerstenbrand F, Fritsch P. Progressive systemic sclerosis and nervous system involvement. A review of 14 cases. *Eur Neurol* 1987;26:134-40.
- Dyck PJ, Hunder GG, Dyck PJ. A case-control and nerve biopsy study of CREST multiple mononeuropathy. *Neurology* 1997;49:1641-5.
- Farrell DA, Medsger TA Jr. Trigeminal neuropathy in progressive systemic sclerosis. *Am J Med* 1982;73:57-62.
- Fischhoff DK, Sirois D. Painful trigeminal neuropathy caused by severe mandibular resorption and nerve compression in a patient with systemic sclerosis: case report and literature review. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2000;90:456-9.
- Frech TM, Smith G, Reily M, Chamberlain J, Murtaugh MA, Penrod J, et al. Peripheral neuropathy: a complication of systemic sclerosis. *Clin Rheumatol* 2013;32:885-8.
- Hietarinta M, Ilonen J, Lassila O, Hietaharju A. Association of HLA antigens with anti-Scl-70-antibodies and clinical manifestations of systemic sclerosis (scleroderma). *Br J Rheumatol* 1994;33:323-6.
- Hietarinta M, Lassila O, Hietaharju A. Association of anti-U1RNP- and anti-Scl-70-antibodies with neurological manifestations in systemic sclerosis (scleroderma). *Scand J Rheumatol* 1994;23:64-7.
- Iskandar SB, Loyd S, Roy TM. Cranial nerve VIII involvement in a patient with progressive systemic sclerosis. *Tenn Med* 2004; 97:117-9.
- Jiménez-Caballero PE, Garrido-Robres JA, Cano-Vargas Machuca E, Marsal-Alonso C, Alvarez-Tejerina A. [CRST syndrome and polyneuropathy]. [Article in Spanish] *Rev Neurol* 2004;38:1092-3.
- Kabadi UM, Sinkoff MW. Trigeminal neuralgia in progressive systemic sclerosis. *Postgrad Med* 1977;61:176-7.
- Langevitz P, Buskila D, Lee P. Ilioinguinal nerve entrapment in a patient with systemic sclerosis (scleroderma). *Clin Rheumatol* 1993;12:540-1.
- Lee P, Bruni J, Sukenik S. Neurological manifestations in systemic sclerosis (scleroderma). *J Rheumatol* 1984;11:480-3.

32. Leichenko T, Herrick AL, Alani SM, Hilton RC, Jayson MI. Mononeuritis in two patients with limited cutaneous systemic sclerosis. *Br J Rheumatol* 1994;33:594-5.
33. Lori S, Matucci-Cerinic M, Casale R, Generini S, Lombardi A, Pignone A, et al. Peripheral nervous system involvement in systemic sclerosis: the median nerve as target structure. *Clin Exp Rheumatol* 1996;14:601-5.
34. Machet L, Vaillant L, Machet MC, Esteve E, Muller C, Khallouf R, et al. Carpal tunnel syndrome and systemic sclerosis. *Dermatology* 1992;185:101-3.
35. Manneschi LI, Del Rosso A, Milia AF, Tani A, Nosi D, Pignone A, et al. Damage of cutaneous peripheral nervous system evolves differently according to the disease phase and subset of systemic sclerosis. *Rheumatology* 2005;44:607-13.
36. Marangoni RG, Rocha LF, Del Rio APT, Yoshinari NH, Marques-Neto JF, Sampaio-Barros PD. Systemic sclerosis sine scleroderma: distinct features in a large Brazilian cohort. *Rheumatology* 2013;52:1520-4.
37. Mejias E. Superior oblique muscle paralysis in the CREST syndrome. *P R Health Sci J* 1986;5:27-9.
38. Morelli S, Piccirillo G, Fimognari F, Sgreccia A, Ferrante L, Morabito G, et al. Twenty-four hour heart period variability in systemic sclerosis. *J Rheumatol* 1996;23:643-5.
39. Moullick A, Sarkar BS, Jana A, Guha P, Das A. Systemic sclerosis presenting with simultaneous retinal vasculitis in one eye and optic neuritis in the other along with severe immune haemolytic anaemia. *J Clin Diagn Res* 2013;7:2978-80.
40. Mouthon L, Halimi C, Muller GP, Cayre-Castel M, Bégué T, Masquelet AC, et al. Systemic scleroderma associated with bilateral ulnar nerve entrapment at the elbow. *Rheumatology* 2000;39:682-3.
41. Nitta Y, Sobue G. Progressive systemic sclerosis associated with multiple mononeuropathy. *Dermatology* 1996;193:22-6.
42. Nobuhara Y, Saito M, Goto R, Yoshidome Y, Kawamura M, Kasai T, et al. Chronic progressive sensory ataxic neuropathy associated with limited systemic sclerosis. *J Neurol Sci* 2006;241:103-6.
43. Ortiz JR, Newman NJ, Barrow DL. CREST-associated multiple intracranial aneurysms and bilateral optic neuropathies. *J Clin Neuroophthalmol* 1991;11:233-40.
44. Ostojic P, Jovic T, Stojic B. Restless legs syndrome in patients with systemic sclerosis. Prevalence and possible causes. *Z Rheumatol* 2013;72:590-3.
45. Paik JJ, Mammen AL, Wigley FM, Shah AA, Hummers LK, Polydefkis M. Symptomatic and electrodiagnostic features of peripheral neuropathy in scleroderma. *Arthritis Care Res* 2016;68:1150-7.
46. Pal B. Carpal tunnel syndrome as a herald of autoimmune rheumatic disorders. *J R Soc Med* 1997;90:216-7.
47. Polio JL, Stern PJ. Digital nerve calcification in CREST syndrome. *J Hand Surg Am* 1989;14:201-3.
48. Poncelet AN, Connolly MK. Peripheral neuropathy in scleroderma. *Muscle Nerve* 2003;28:330-5.
49. Provitera V, Nolano M, Pappone N, di Girolamo C, Stancanelli A, Lullo F, et al. Distal degeneration of sensory and autonomic cutaneous nerve fibres in systemic sclerosis. *Ann Rheum Dis* 2005;64:1524-6.
50. Quinones CA, Perry HO, Rushton JG. Carpal tunnel syndrome in dermatomyositis and scleroderma. *Arch Dermatol* 1966;94:20-5.
51. Roustit M, Simmons GH, Carpentier P, Cracowski JL. Abnormal digital neurovascular response to local heating in systemic sclerosis. *Rheumatology* 2008;47:860-4.
52. Sant SM, Murphy GM. Neurotropic ulceration in systemic sclerosis. *Clin Exp Dermatol* 1994;19:65-6.
53. Schady W, Sheard A, Hassell A, Holt L, Jayson MI, Klimiuk P. Peripheral nerve dysfunction in scleroderma. *Q J Med* 1991; 80:661-75.
54. Skare TL, Fonseca AE, Luciano AC, Azevedo PM. Autoantibodies in scleroderma and their association with the clinical profile of the disease. A study of 66 patients from southern Brazil. *An Bras Dermatol* 2011;86:1075-81.
55. Stacher G, Merio R, Budka C, Schneider C, Smolen J, Tappeiner G. Cardiovascular autonomic function, autoantibodies, and esophageal motor activity in patients with systemic sclerosis and mixed connective tissue disease. *J Rheumatol* 2000;27:692-7.
56. Sukenik S, Abarbanel JM, Buskila D, Potashnik G, Horowitz J. Impotence, carpal tunnel syndrome and peripheral neuropathy as presenting symptoms in progressive systemic sclerosis. *J Rheumatol* 1987;14:641-3.
57. Tagliafico A, Panico N, Resmini E, Derchi LE, Ghio M, Martinoli C. The role of ultrasound imaging in the evaluation of peripheral nerve in systemic sclerosis (scleroderma). *Eur J Radiol* 2011; 77:377-82.
58. Thompson PD, Robertson GJ. Trigeminal neuropathy heralding scleroderma: a report of a case. *J Maine Med Assoc* 1973;64:123-4.
59. Fouca NM, Abdel-Halim M, Forbes A, Denton CP, Emmanuel AV. Fecal incontinence in systemic sclerosis is secondary to neuropathy. *Am J Gastroenterol* 2012 Apr;107:597-603.
60. Thurman RT, Jindal P, Wolff TW. Ulnar nerve compression in Guyon's canal caused by calcinosis in scleroderma. *J Hand Surg Am* 1991;16:739-41.
61. Agarwal R, Vasani RS, Singh RR, Saxena SP, Bhadoria DP, Srivastava AK, et al. Trigeminal and peripheral neuropathy in a patient with systemic sclerosis and silicosis. *Clin Exp Rheumatol* 1987;5:375-6.
62. Ashworth B, Tait GB. Trigeminal neuropathy in connective tissue disease. *Neurology* 1971;21:609-14.
63. Beighton P, Gumpel JM, Cornes NG. Prodromal trigeminal sensory neuropathy in progressive systemic sclerosis. *Ann Rheum Dis* 1968;27:367-9.
64. Berth-Jones J, Coates PA, Graham-Brown RA, Burns DA. Neurological complications of systemic sclerosis—a report of three cases and review of the literature. *Clin Exp Dermatol* 1990;15:91-4.
65. Birk MA, Zeuthen EL. Phrenicus palsy in progressive systemic sclerosis. *Br J Rheumatol* 1995;34:684-5.
66. Burke MJ, Carty JE. Trigeminal neuropathy as the presenting symptom of systemic sclerosis. *Postgrad Med J* 1979;55:423-5.
67. Gumpel JM. Trigeminal sensory neuropathy in connective-tissue disease. *N Engl J Med* 1970;282:514.
68. Hietaharju A, Jääskeläinen S, Kalimo H, Hietarinta M. Peripheral neuromuscular manifestations in systemic sclerosis (scleroderma). *Muscle Nerve* 1993;16:1204-12.
69. Jimenez-Moreno J, Selva-O'Callaghan A, Rovira-Cañellas A, Solans-Laqué R, Len O, Olias M, et al. Trigeminal sensory neuropathy in systemic sclerosis. *Br J Rheumatol* 1998;37:587-9.
70. Kaufmann J, Canoso JJ. Progressive systemic sclerosis and meralgia paraesthetica. *Ann Intern Med* 1986;105:973.
71. Knupp-Oliveira S, Cerinic MM. Polyneuropathy as initial manifestation of systemic sclerosis (scleroderma). *Scand J Rheumatol* 1999;28:260-1.
72. Lima IV, Galvão LA, Maia TS, Santiago MB. Spinal cord compression by ectopic calcinosis in scleroderma. *Clin Exp Rheumatol* 2005;23:704-6.
73. Miguel D, Darr-Foit S, Tittelbach J, Elsner P. Trigeminal neuropathy responding to systemic corticosteroids and methotrexate in a patient with diffuse cutaneous systemic sclerosis. *Eur J Dermatol* 2017;27:82-3.
74. Mondeli M, Romano C, Della Porta P, Rossi A. Electrophysiological evidence of "nerve entrapment syndromes" and subclinical peripheral neuropathy in progressive systemic sclerosis (scleroderma). *J Neurol* 1995;242:185-94.

75. Mouthon L, Halimi C, Dussaule JC, Cayre-Castel M, Guillevin L. Brachial plexopathy associated with diffuse edematous scleroderma. *Ann Med Interne* 2000;151:303-5.
76. Rudusky BM. Neurologic manifestations of collagen disease: a report of four cases. *Pa Med J* 1964;67:30-4.
77. Widuchowska M, Kotulska A, Kopeć-Medrek M, Kucharz EJ. Carpal tunnel syndrome as the early symptom of rapidly progressive systemic sclerosis in men. *Wiad Lek*. 2010;63:33.
78. Casey EB, Lawton NF. Progressive systemic sclerosis presenting with Raynaud's phenomenon in the tongue and sensory trigeminal neuropathy. *Rheumatol Phys Med* 1971;11:131-3.
79. Dimitriu R, Stamatoiu I, Nicolae I, Ciobanu I. Scleroderma and its relationship to nervous system disease. Report of a case. *Neurol Psychiatr* 1977;15:117-23.
80. Berrut G, Gaubert ML, Barré J. [Plexopathy associated with systemic scleroderma]. [Article in French] *Rev Med Interne* 2002;23:478-9.
81. Clement GB, Grizzard K, Vasey FB, Germain BF, Espinoza LR. Neuropathic arthropathy (Charcot joints) due to cervical osteolysis: a complication of progressive systemic sclerosis. *J Rheumatol* 1984;11:545-8.
82. Di Trapani G, Pocchiarri M, Masullo C, Albanese A, Tulli A. Peripheral neuropathy in the course of progressive systemic sclerosis: light and ultrastructural study. *Ital J Neurol Sci* 1982;3:341-8.
83. Grachev JV, Anan'eva LP, Tjurnikov VM, Zaharova AJ. [A case report of bilateral trigeminal sensory neuropathy as one of the initial manifestation of systemic scleroderma (the difficulties of early diagnosis of the primary disease)]. [Article in Russian] *Zh Nevrol Psikhiatr Im S S Korsakova* 2015;115:59-63.
84. Ko CY, Jones NF, Steen VD. Compression of the median nerve proximal to the carpal tunnel in scleroderma. *J Hand Surg Am* 1996;21:363-5.
85. Koratala A, Kamboj M, Bhatti V. Ulnar neuropathy in a patient with systemic sclerosis. *Am J Med* 2018;131:e93-4.
86. Levy Y, Uziel Y, Zandman G, Rotman P, Amital H, Sherer Y, et al. Response of vasculitic peripheral neuropathy to intravenous immunoglobulin. *Ann N Y Acad Sci* 2005;1051:779-86.
87. Matthews NS. Scleroderma presents as facial hypoaesthesia. *Br Dent J* 2000;189:183-4.
88. Moore ME, Burke JM, Hartman JH, Korenzwitt E. Lumbosacral plexopathy in a woman with CREST syndrome and vasculitis. *Arthritis Rheum* 1989;32:661-3.
89. Ofstad E. Scleroderma (progressive systemic sclerosis). A case involving polyneuritis and swelling of the lymph nodes. *Acta Rheumatol Scand* 1960;6:65-75.
90. Pinstein ML, Sebes JJ, Leventhal M, Robertson JT. Case report 579: progressive systemic sclerosis (PSS) with cervical cord compression syndrome, osteolysis and bilateral facet arthropathy. *Skeletal Radiol* 1989;18:603-5.
91. Shibuya S, Kawaguchi Y, Arima N, Yamamoto T, Dobashi H, Tokuda M. Tumoral calcinosis in bilateral facet joints of the lumbar spine in scleroderma. Case report. *J Neurosurg Spine* 2006;5:451-4.
92. Butt S, Alam A, Raeburn AJ, Liwanag J, Ong V, Denton C, et al. Significant findings from a randomised control trial of posterior tibial nerve stimulation in systemic sclerosis associated faecal incontinence. *Gastroenterology* 2015;148 Suppl 1:S307.
93. Corbo M, Nemni R, Iannaccone S, Quattrini A, Lodi M, Praderio L, et al. Peripheral neuropathy in scleroderma. *Clin Neuropathol* 1993;12:63-7.
94. Di Trapani G, Tulli A, La Cara A, Laurienzo P, Mazza S, David P. Peripheral neuropathy in course of progressive systemic sclerosis. Light and ultrastructural study. *Acta Neuropathol* 1986;72:103-10.
95. Lecky BR, Hughes RA, Murray NM. Trigeminal sensory neuropathy. A study of 22 cases. *Brain* 1987;110:1463-85.
96. Rohrmann Jr CA, Ricci MT, Krishnamurthy S, Schuffer MD. Radiologic and histologic differentiation of neuromuscular disorders of the gastrointestinal tract: visceral myopathies, visceral neuropathies, and progressive systemic sclerosis. *AJR Am J Roentgenol* 1984;143:933-41.
97. Tait B, Ashworth B. Trigeminal neuropathy in connective tissue disease. *Ann Rheum Dis* 1970;29:339.
98. Teasdall RD, Frayha RA, Shulman LE. Cranial nerve involvement in systemic sclerosis (scleroderma): a report of 10 cases. *Medicine*. 1980;59:149-59.
99. Vicente A, Herrero C, Martín E, Valls J, Graus F, Mascaró JM. Trigeminal sensory-neuropathy in systemic sclerosis. *Clin Exp Dermatol* 1991;16:403.
100. Christopher RP, Robinson H. Studies of nerve conduction in patients with scleroderma. *South Med J* 1972;65:668-72.
101. DeLea SL, Chavez-Chiang NR, Poole JL, Norton HE, Sibbitt WL Jr, Bankhurst AD. Sonographically guided hydrodissection and corticosteroid injection for scleroderma hand. *Clin Rheumatol* 2011;30:805-13.
102. Giacomini PG, Zoli A, Ferraro S, Raffaldi AV, Bartolozzi F, Di Girolamo S. Evaluation of abnormalities of orthostatic postural control in systemic sclerosis. *Clin Exp Rheumatol*. 2005;23:297-302.
103. Serup J. Tactile sensitivity in systemic sclerosis. Assessment of two-point and circle discriminations of the digit. *Dermatologica* 1984;168:279-82.
104. Sonnex C, Paice E, White AG. Autonomic neuropathy in systemic sclerosis: a case report and evaluation of six patients. *Ann Rheum Dis* 1986;45:957-60.
105. Yagci I, Kenis-Coskun O, Ozsoy T, Ozen G, Direskeneli H. Increased stiffness of median nerve in systemic sclerosis. *BMC Musculoskelet Disord* 2017;18:434.
106. Dahlgard T, Nielsen VK, Kristensen JK. Vibratory perception in patients with generalized scleroderma. *Acta Derm Venereol* 1980;60:119-22.
107. McNearney TA, Sallam HS, Hunnicutt SE, Doshi D, Chen JD. Prolonged treatment with transcutaneous electrical nerve stimulation (TENS) modulates neuro-gastric motility and plasma levels of vasoactive intestinal peptide (VIP), motilin and interleukin-6 (IL-6) in systemic sclerosis. *Clin Exp Rheumatol* 2013;31 Suppl 76:140-50.
108. Sollberg G, Denk R, Holzmann H. [Neurological and electrophysiological studies in progressive scleroderma and morphea]. [Article in German] *Arch Klin Exp Dermatol* 1967;229:20-32.
109. Stojanovich L, Milovanovich B, de Luka SR, Popovich-Kuzmanovich D, Bisenich V, Djukanovich B, et al. Cardiovascular autonomic dysfunction in systemic lupus, rheumatoid arthritis, primary Sjogren syndrome and other autoimmune diseases. *Lupus* 2007;16:181-5.
110. Straub RH, Andus T, Lock G, Zeuner M, Palitzsch KD, Gross V, et al. [Cardiovascular and pupillary autonomic neuropathy and sensorimotor neuropathy in chronic diseases with autoimmune phenomena. A comparative study in patients with Crohn's disease, ulcerative colitis, systemic lupus erythematosus, systemic sclerosis and insulin-dependent diabetes mellitus]. [Article in German] *Med Klin* 1997;92:647-53.
111. Straub RH, Zeuner M, Lock G, Rath H, Hein R, Schölmerich J, et al. Autonomic and sensorimotor neuropathy in patients with systemic lupus erythematosus and systemic sclerosis. *J Rheumatol* 1996;23:87-92.
112. Terenghi G, Bunker CB, Liu YF, Springall DR, Cowen T, Dowd PM, et al. Image analysis quantification of peptide-immunoreactive nerves in the skin of patients with Raynaud's phenomenon and systemic sclerosis. *J Pathol* 1991;164:245-52.

113. Badakov S. Ultrastructural changes of cutaneous nerves in scleroderma. *Folia Medica* 1992;34:57-64.
114. Barbosa NS, Wetter DA, Wieland CN, Shenoy NK, Markovic SN, Thanarajasingam U. Scleroderma induced by pembrolizumab: a case series. *Mayo Clin Proc* 2017;92:1158-63.
115. Benito-León J, Miguélez R, Vincent A, Masjuán J, de Blas G. Neuromyotonia in association with systemic sclerosis. *J Neurol* 1999;246:976-7.
116. Calore EE, Cavaliere MJ, Perez NM, Takayasu V, Wakamatsu A, Kiss MH. Skeletal muscle pathology in systemic sclerosis. *J Rheumatol* 1995;22:2246-2249.
117. Korting GW, Klee W. [Morphologic knowledge of polyneuropathy in progressive scleroderma]. [Article in German] *Hautarzt* 1984;35:425-7.
118. Lonsdorf G. Karpaltunnelsyndrom bei diffuser Sklerodermie [Carpal tunnel syndrome in diffuse scleroderma]. [Article in German] *Hautarzt* 1979;30(3):158-60.
119. Andreadou E, Zouvelou V, Karandreas N, Kilidireas C. Anti-myelin-associated glycoprotein polyneuropathy coexistent with CREST syndrome. *J Postgrad Med* 2012;58:57-9.
120. Averbuch-Heller L, Steiner I, Abramsky O. Neurologic manifestations of progressive systemic sclerosis. *Arch Neurol* 1992;49:1292-5.
121. Oddis CV, Eisenbeis CH Jr, Reidbord HE, Steen VD, Medsger TA Jr. Vasculitis in systemic sclerosis: association with Sjögren's syndrome and the CREST syndrome variant. *J Rheumatol* 1987;14:942-8.
122. Said G, Lacroix-Ciaudo C, Fujimura H, Blas C, Faux N. The peripheral neuropathy of necrotizing arteritis: a clinicopathological study. *Ann Neurol* 1988;23:461-5.
123. Johnson SR, Khanna D, Allanore Y, Matucci-Cerinic M, Furst DE. Systemic sclerosis trial design moving forward. *J Scleroderma Relat Disord.* 2016;1:177-80.